Cargando…
Surgical choroidal neovascular membrane removal in the era of anti-vascular endothelial growth factor agents
Intravitreal anti-vascular endothelial growth factor (VEGF) agents have obtained acceptance as the mainstay in the management strategy of subfoveal choroidal neovascular membranes (CNVM) due to varying etiologies. Few drawbacks include need for repeated intravitreal injections, with its adjunct risk...
Autores principales: | Nagpal, Manish, Nagpal, Kamal, Mehta, Vikram |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684435/ https://www.ncbi.nlm.nih.gov/pubmed/19237791 http://dx.doi.org/10.4103/0301-4738.45507 |
Ejemplares similares
-
Choroidal neovascularization in a case of angioid streaks
por: Nagpal, Manish, et al.
Publicado: (2013) -
A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
por: Nagpal, Manish, et al.
Publicado: (2007) -
Choroidal neovascular membrane in a treated choroidal hemangioma
por: Nagesha, Chokkahalli K, et al.
Publicado: (2016) -
Macular Hole Progression after Intravitreal Bevacizumab for Hemicentral Retinal Vein Occlusion
por: Nagpal, Manish, et al.
Publicado: (2011) -
Peripapillary choroidal neovascularization in pars planitis
por: Mehta, Sonia, et al.
Publicado: (2013)